Literature DB >> 2910640

Oral dipyridamole increases plasma adenosine levels in human beings.

D C German1, N M Kredich, T D Bjornsson.   

Abstract

Plasma adenosine levels in five healthy volunteers for 5 consecutive days showed far less intrasubject than intersubject variation (p less than 0.0001), indicating that plasma adenosine levels are relatively constant during this period. Plasma adenosine levels were then measured in a different group of five healthy subjects for a 5-day control period and during a 5-day course of oral dipyridamole at a dose of 100 mg every 6 hours. Intrasubject comparisons showed that plasma adenosine levels were significantly higher during the 5 days of dipyridamole administration than during the control period (p = 0.017) and that this increase was most significant after 48 hours of drug (p less than 0.001) administration. The average increase was 0.133 mumol/L (60%) with a range of 0.063 to 0.197 mumol/L (37% to 212%) during the last 3 days. A significant positive correlation was noted between plasma adenosine and dipyridamole levels (p = 0.001). We conclude that adenosine levels are relatively stable for an individual and are maximally increased after 2 days of oral dipyridamole.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910640     DOI: 10.1038/clpt.1989.12

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Adenosine and the adaptation to exercise.

Authors:  R E Simpson; J W Phillis
Journal:  Sports Med       Date:  1993-04       Impact factor: 11.136

Review 2.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

3.  Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial.

Authors:  M P Heintzen; U E Heidland; W J Klimek; M Leschke; M Kelm; B Schwartzkopff; E G Vester; C J Michel; B E Strauer
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

Review 4.  Adenosine in exercise adaptation.

Authors:  R E Simpson; J W Phillis
Journal:  Br J Sports Med       Date:  1992-03       Impact factor: 13.800

Review 5.  Translational therapeutics of dipyridamole.

Authors:  Hyung-Hwan Kim; James K Liao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-03       Impact factor: 8.311

6.  Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection.

Authors:  G A Rongen; P Smits; K Ver Donck; J J Willemsen; R A De Abreu; H Van Belle; T Thien
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

7.  Circulating adenosine increases during human experimental endotoxemia but blockade of its receptor does not influence the immune response and subsequent organ injury.

Authors:  Bart P Ramakers; Niels P Riksen; Petra van den Broek; Barbara Franke; Wilbert H M Peters; Johannes G van der Hoeven; Paul Smits; Peter Pickkers
Journal:  Crit Care       Date:  2011-01-06       Impact factor: 9.097

Review 8.  The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder.

Authors:  Maria Carolina Bittencourt Gonçalves; Roberta Andrejew; Carolina Gubert
Journal:  CNS Drugs       Date:  2022-07-13       Impact factor: 6.497

9.  High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.

Authors:  Serena Cappato; Laura Tonachini; Francesca Giacopelli; Mario Tirone; Luis J V Galietta; Martina Sormani; Anna Giovenzana; Antonello E Spinelli; Barbara Canciani; Silvia Brunelli; Roberto Ravazzolo; Renata Bocciardi
Journal:  Dis Model Mech       Date:  2016-04-28       Impact factor: 5.758

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.